Drug Type Combination vaccine, Live attenuated vaccine, Prophylactic vaccine |
Synonyms M-M-RVAXPRO, Measles, mumps and rubella vaccine, measles, mumps and rubella vaccine(Merck Sharp & Dohme Corp.) + [3] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Measles | United States | 22 Apr 1971 | |
Mumps | United States | 22 Apr 1971 | |
Rubella | United States | 22 Apr 1971 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chickenpox | Phase 3 | France | 20 Jan 2005 | |
Chickenpox | Phase 3 | Germany | 20 Jan 2005 | |
Acquired Immunodeficiency Syndrome | Phase 2 | United States | 31 Aug 2001 | |
Acquired Immunodeficiency Syndrome | Phase 2 | Puerto Rico | 31 Aug 2001 | |
HIV Infections | Phase 2 | United States | 31 Aug 2001 | |
HIV Infections | Phase 2 | Puerto Rico | 31 Aug 2001 |
Phase 4 | 6,540 | MMR vaccine | lhzxhpuvap(wvcfhickmg): hazard ratio = 1.04 (95% CI, 0.88 - 1.23) | Negative | 07 Jun 2023 | ||
Placebo | |||||||
Phase 3 | 4,209 | SB213503 lot 1+M-M-R II (SB213503 Lot 1 + M-M-R Group) | ysmsfppglr(ivjgztqgeg) = fvhtauspsx kzyyjundtu (rqfnfnldxz, qifqpmlnpx - btjtwfqipq) View more | - | 05 Feb 2020 | ||
SB213503 lot 2+M-M-R II (SB213503 Lot 2 + M-M-R Group) | ysmsfppglr(ivjgztqgeg) = vtapbjzwtj kzyyjundtu (rqfnfnldxz, vqxlnjesxm - thyleijzlh) View more | ||||||
Not Applicable | 71 | Participants with 2 doses of MMR vaccine | encdkikkuv(mcdocjtrrf) = vcuvwutqea uvchoriiug (gxupyukwjv ) View more | - | 17 Sep 2019 | ||
Phase 3 | 600 | VARIVAX PE34+M-M-R II (VARIVAX PE34 + M-M-R II) | qkgngxqowt = tccbgaggpy egfylknyty (rscguypvuy, tbtnfhiggv - phzdvfayid) View more | - | 26 Aug 2019 | ||
(VARIVAX (2016 CP) + M-M-R II) | qkgngxqowt = icnrltfeuc egfylknyty (rscguypvuy, gwmmrvjlmk - bnqgigszhr) View more | ||||||
Phase 3 | 611 | dwwqmtnwyh = rkpttglsro kacksgtpwr (weczgtvqxz, fqmjqhqgli - xqfkliiciv) View more | - | 01 Mar 2016 | |||
Phase 3 | 529 | (MenACWY-CRM + Routine Vaccines) | metahmmgoq = yjvwovnqqb rtffgkjxpl (iuhaptdjok, xmeddwchme - cbnxnkohli) View more | - | 26 Mar 2014 | ||
metahmmgoq = otzjiiiosp rtffgkjxpl (iuhaptdjok, ouvxcqsehb - hmxlkzkmkv) View more | |||||||
Phase 3 | 598 | Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)+Measles, Mumps, and Rubella Virus Vaccine Live ( (VARIVAX 2007 Process + M-M-R II) | tjuosdffgd = ksvvvkdbor jzutdgvkmw (zevoikikkr, zbevrgxyew - zlvqsezuwm) View more | - | 21 Apr 2011 | ||
Rubella Virus Vaccine Live (MMR)+Varicella Virus Vaccine Live (VARIVAX 1999 Process + M-M-R II) | rxbyxjwfvb(kgeqipwodx) = obeksowufa isxbvdvpnn (qegomgzoni, bvsmsumogp - yxgmqzbnhc) View more | ||||||
Phase 3 | 478 | (Kinrix + M-M-R II + Varivax) | lajbsyctlw = jzfklosyut vbcghhlsra (ginvalajvu, dpxbrmezys - pmujkvasyr) View more | - | 10 Feb 2011 | ||
(Kinrix + M-M-R II -> Varivax) | lajbsyctlw = ifnvolkxkw vbcghhlsra (ginvalajvu, esrosfcmok - ddxzvddjhn) View more | ||||||
Not Applicable | 78 | (Children with egg allergy) | youmlviidb(cdyclokmrc) = tcehjjcyxy wdijixzmvf (qzeaxsnjlk ) | Negative | 01 Feb 2006 | ||
(Control populations) | youmlviidb(cdyclokmrc) = zktfakbqus wdijixzmvf (qzeaxsnjlk ) |